<DOC>
	<DOCNO>NCT00299507</DOCNO>
	<brief_summary>The purpose study evaluate effect dose concentration administration frequency Anecortave Acetate ( AA ) visual acuity ( VA ) lesion size administer posterior juxtascleral depot ( PJD ) every 3 month ( AA 15 mg ) 6 month ( AA 15 mg , AA 30 mg ) patient exudative age-related macular degeneration ( AMD ) .</brief_summary>
	<brief_title>Anecortave Acetate Patients With Exudative Age-related Macular Degeneration ( AMD )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Anecortave</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Clinical diagnosis exudative AMD primary recurrent ( laser photocoagulation ) subfoveal choroidal neovascularization ( CNV ) lesion . Other protocoldefined inclusion criterion may apply . Less 50 year age . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>exudative AMD</keyword>
	<keyword>age-related macular degeneration ( AMD )</keyword>
</DOC>